Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN
AuthorsMcAdoo, Stephen P.
McDaid, John P.
Jackson, William D.
Masuda, Esteban S.
Cook, H. Terence
Pusey, Charles D.
Tam, Frederick W.K.
Subjectsspleen tyrosine kinase
MetadataShow full item record
AbstractSpleen tyrosine kinase (SYK) has an important role in immunoreceptor signaling, and SYK inhibition has accordingly attenuated immune-mediated injury in several in vivo models. However, the effect of SYK inhibition on autoantibody production remains unclear, and SYK inhibition has not been studied in an autoimmune model of renal disease. We, therefore, studied the effect of SYK inhibition in experimental autoimmune GN, a rodent model of antiglomerular basement membrane disease. We show glomerular SYK expression and activation by immunohistochemistry in both experimental and clinical disease, and we show that treatment with fostamatinib, a small molecule kinase inhibitor selective for SYK, completely prevents the induction of experimental autoimmune GN. In established experimental disease, introduction of fostamatinib treatment led to cessation of autoantibody production, reversal of renal injury, preservation of biochemical renal function, and complete protection from lung hemorrhage. B cell ELISpot and flow cytometric analysis suggest that short-term fostamatinib treatment inhibits the generation and activity of antigen-specific B cells without affecting overall B-cell survival. Additionally, fostamatinib inhibited proinflammatory cytokine production by nephritic glomeruli ex vivo and cultured bone marrow-derived macrophages in vitro, suggesting additional therapeutic effects independent of effects on autoantibody production that are likely related to inhibited Fc receptor signaling within macrophages in diseased glomeruli. Given these encouraging results in an in vivo model that is highly applicable to human disease, we believe clinical studies targeting SYK in GN are now warranted.
CitationMcAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FWK (2014) 'Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN', Journal of the American Society of Nephrology : JASN, 25 (10), pp.2291-302.
PublisherAmerican Society of Nephrology
PubMed Central IDPMC4178438
- Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
- Authors: Pamuk ON, Can G, Ayvaz S, Karaca T, Pamuk GE, Demirtas S, Tsokos GC
- Issue date: 2015 Jul-Aug
- Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression.
- Authors: Lindau A, Härdtner C, Hergeth SP, Blanz KD, Dufner B, Hoppe N, Anto-Michel N, Kornemann J, Zou J, Gerhardt LM, Heidt T, Willecke F, Geis S, Stachon P, Wolf D, Libby P, Swirski FK, Robbins CS, McPheat W, Hawley S, Braddock M, Gilsbach R, Hein L, von zur Mühlen C, Bode C, Zirlik A, Hilgendorf I
- Issue date: 2016 Mar
- Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
- Authors: Leonhardt F, Zirlik K, Buchner M, Prinz G, Hechinger AK, Gerlach UV, Fisch P, Schmitt-Gräff A, Reichardt W, Zeiser R
- Issue date: 2012 Jul
- Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
- Authors: Bajpai M
- Issue date: 2009 Mar
- A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
- Authors: Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FW
- Issue date: 2010 Feb